Clinical Trial Update: Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial evaluating loncastuximab tesirine (ADCT-402) in relapsed/refractory marginal zone lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Zynlonta (loncastuximab tesirine)

Snippet

Sponsor: University of Miami | Conditions: Marginal Zone Lymphoma | Phase 2 | Status: RECRUITING